Pembrolizumab: all 1,753 studies that test it
Page 3 of 18. Open to participants first (418), then studies with results posted, then the rest; newest registration first within each.
- Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast CancerNot yet recruitingNCT06407310Phase 2
- Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor ThrombosisRecruitingNCT06389422Phase 2
- Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)RecruitingNCT06384560Phase 1/2
- Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid TumorsRecruitingNCT06384352Phase 1
- A Study of BV-AVD in People With Bulky Hodgkin LymphomaRecruitingNCT06377566Phase 2
- MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin LymphomaRecruitingNCT06377540Phase 2
- Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid CancerRecruitingNCT06374602Phase 2
- Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With PembrolizumabNot yet recruitingNCT06371807Phase 2
- DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLCRecruitingNCT06364917Phase 2
- CARE1 Pragmatic Clinical TrialRecruitingNCT06364631Phase 3
- Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial CancerRecruitingNCT06356155Phase 2
- Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC PatientsRecruitingNCT06353997Phase 2
- Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile CancerRecruitingNCT06353906Phase 2
- Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric AdenocarcinomaRecruitingNCT06340711Phase 2
- A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)RecruitingNCT06312176Phase 3
- Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary CarcinomaRecruitingNCT06302569Phase 2
- Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid TumorsRecruitingNCT06293651Phase 1/2
- Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV InfectionNot yet recruitingNCT06276504Phase 2/3
- A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsRecruitingNCT06270706Phase 1
- Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)RecruitingNCT06266338Phase 2
- GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid TumorsRecruitingNCT06265025Phase 1/2
- Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With PembrolizumabRecruitingNCT06249048Phase 1/2
- PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBCRecruitingNCT06245889Phase 2
- Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid TumorsRecruitingNCT06234397Phase 1
- Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract CancerRecruitingNCT06230471Phase 2
- Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell CarcinomaRecruitingNCT06211335Phase 1
- Drug Screening Using IMD in Bladder CancerEnrolling by invitationNCT06204614Early Phase 1
- A Study Comparing Pharmacokinetic and Safety of QL2107 and Keytruda® (Marketed in China and the United States) in Healthy AdultsRecruitingNCT06173011Phase 1
- Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCRecruitingNCT06162221Phase 1/2
- PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical CancerRecruitingNCT06157151Phase 2
- Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant TherapyNot yet recruitingNCT06146777Phase 3
- A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.Not yet recruitingNCT06142617Phase 2
- European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]RecruitingNCT06137378Phase 2
- A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric CancerRecruitingNCT06123338Phase 2
- Palbociclib and Pembrolizumab in SarcomaRecruitingNCT06113809Phase 1
- JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid TumorsRecruitingNCT06108050Phase 1
- Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCCRecruitingNCT06102395Phase 3
- Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCCRecruitingNCT06100497Phase 2
- Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline TherapyRecruitingNCT06083844Phase 2
- NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)RecruitingNCT06081244Phase 3
- Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBCRecruitingNCT06078384Phase 2
- Study of Radiotherapy and Pembrolizumab in People With Adrenocortical CarcinomaRecruitingNCT06066333Phase 2
- Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCCRecruitingNCT06052839Phase 2
- T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung CancerNot yet recruitingNCT06045767Phase 2
- Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin LymphomaNot yet recruitingNCT06045195Phase 2
- Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)RecruitingNCT06041503Phase 2
- Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieRecruitingNCT06031233Phase 4
- Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC PatientsNot yet recruitingNCT06028633Phase 2
- Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical CancerRecruitingNCT06006013Phase 2
- Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)RecruitingNCT06005818Phase 2
- A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)RecruitingNCT06004336Phase 2
- Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract CancersRecruitingNCT06001658Phase 2
- Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor ThrombusRecruitingNCT05969496Phase 2
- A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic CholangiocarcinomaRecruitingNCT05967182Phase 2
- Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma PatientsRecruitingNCT05961761Phase 2
- Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309RecruitingNCT05957081Phase 1
- Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell LymphomasRecruitingNCT05956041Phase 2
- Pembro Plus CAR T-cell Therapy in R/R in PMBCLRecruitingNCT05934448Phase 2
- Pembrolizumab in Locally Advanced Sinonasal CarcinomaRecruitingNCT05925491Phase 2
- Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal CancerNot yet recruitingNCT05909423Phase 2
- Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or RadiotherapyRecruitingNCT05903833Phase 2
- Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)RecruitingNCT05879653Phase 2
- Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic CancerRecruitingNCT05877430Phase 1/2
- Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)RecruitingNCT05872867Phase 1
- A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor CancerRecruitingNCT05859074Phase 1
- Pembrolizumab in High-risk Thyroid CancerRecruitingNCT05852223Phase 2
- A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)RecruitingNCT05849480Phase 1/2
- First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)RecruitingNCT05832827Phase 2
- A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)RecruitingNCT05824975Phase 1/2
- pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal CancerRecruitingNCT05799144Phase 2
- Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid TumorsRecruitingNCT05784688Phase 1/2
- Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung CancerRecruitingNCT05777603Phase 1
- Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial CancerRecruitingNCT05775471Phase 2
- Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate CancerRecruitingNCT05766371Phase 2
- A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849RecruitingNCT05761223Phase 1/2
- Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant HistologyRecruitingNCT05756569Phase 2
- A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid TumorsRecruitingNCT05746897Phase 1
- Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine TumorsRecruitingNCT05746208Phase 2
- First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLCRecruitingNCT05745350Phase 2
- Intraperitoneal Immune Checkpoint Inhibitor for Malignant AscitesEnrolling by invitationNCT05745233Not applicable
- Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast CancerRecruitingNCT05741164Phase 2
- Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)RecruitingNCT05733689Phase 1
- Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.RecruitingNCT05727904Phase 3
- Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCCRecruitingNCT05726370Phase 2
- Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingNCT05725200Phase 2
- A Study of EBC-129 in Advanced Solid TumoursRecruitingNCT05701527Phase 1
- Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority StudyRecruitingNCT05692999Phase 3
- Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue SarcomaRecruitingNCT05679921Phase 2
- Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLCRecruitingNCT05669846Phase 2
- A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor MalignanciesRecruitingNCT05669430Phase 1/2
- Renal Retention in High Grade Upper Tract Urothelial CancerRecruitingNCT05656235Phase 2
- Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction AdenocarcinomaRecruitingNCT05651594Phase 2
- A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic NeoplasiaRecruitingNCT05635344Phase 2
- Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)RecruitingNCT05623319Phase 2
- A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)RecruitingNCT05613413Phase 2
- Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial CarcinomaRecruitingNCT05603910Phase 1
- Pembrolizumab for Advanced NSCLC and PS 2-3RecruitingNCT05589818Phase 2
- SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung CancerRecruitingNCT05570825Phase 2
- Pembrolizumab Plus Radiotherapy for Advanced Renal CancerRecruitingNCT05567588Phase 2
- Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)RecruitingNCT05563558Phase 2